Abstract 4231: Preclinical candidate RVU305, an MTA-cooperative PRMT5 inhibitor, shows activity in MTAP-deleted tumors resistant to immune checkpoint treatmentAnna Bartosik, Krzysztof Brzózka, Kamil Kuś et al.|Cancer Research|2025Cited by 1
Abstract 696: Development of selective CDK8 inhibitors for colorectal cancer and mantle cell lymphoma treatment.Tomasz Rzymski, Krzysztof Brzózka, Adrian Zarębski et al.|Cancer Research|2013Cited by 0